NEW YORK, Dec. 04, 2017 /PRNewswire/ -- In keeping with the commitment to dynamically provide members with timely information,WallStEquities.com has issued free tailored Stock Review on VKTX, RXII, KTOV, and EARS which is a click away at http://www.wallstequities.com/registration. On Friday, December 1, 2017, US markets saw broad based losses
On Friday, shares in San Diego, California headquartered Viking Therapeutics Inc. recorded a trading volume of 727,375 shares, which was above their three months average volume of 682.99 thousand shares. The stock ended the session 0.66% lower at $3.02. The Company's shares have gained 23.77% in the last month, 174.55% over the previous three months, 196.08% in the past twelve months, and 153.78% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 27.94% and 100.47%, respectively. Moreover, shares of Viking Therapeutics, which focuses on the development of therapies for metabolic and endocrine disorders, have a Relative Strength Index (RSI) of 60.94.
On November 28th, 2017, research firm Maxim Group reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $5 a share to $8 a share. Get started with a complimentary subscription and access to the free report on VKTX at: http://www.wallstequities.com/registration/?symbol=VKTX
Marlborough, Massachusetts headquartered RXi Pharmaceuticals Corp.'s stock closed the day 3.28% lower at $0.61 with a total trading volume of 260,209 shares. The Company's shares have advanced 16.66% in the past month. The stock is trading above its 50-day moving average by 8.52%. Additionally, shares of RXi Pharma, which focuses on developing therapeutics for unmet medical needs, have an RSI of 51.56. Free research on RXII can be accessed at: http://www.wallstequities.com/registration/?symbol=RXII
Kitov Pharmaceuticals Holdings
Shares in Jerusalem, Israel-based Kitov Pharmaceuticals Holdings Ltd recorded a trading volume of 71,577 shares. The stock ended last Friday's trading session 0.43% higher at $2.31. The Company's shares have advanced 26.92% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 3.46% and 18.30%, respectively. Furthermore, shares of Kitov Pharma, which engages in developing non-steroidal anti-inflammatory drugs that treat the pain of osteoarthritis without causing cardiovascular problems, have an RSI of 56.36.
On November 21st, 2017, research firm H.C. Wainwright upgraded the Company's stock rating from 'Neutral' to 'Buy', with a target price of $10 per share. Sign up today for the free research report on KTOV at: http://www.wallstequities.com/registration/?symbol=KTOV
Auris Medical Holding
Zug, Switzerland headquartered Auris Medical Holding AG's stock finished Friday's session 3.12% lower at $0.44 with a total trading volume of 1.04 million shares, which was above their three months average volume of 773.48 thousand shares. The stock is trading below its 50-day moving average by 44.27%. Additionally, shares of Auris Medical, which focuses on the development of novel products for the treatment of inner ear disorders, have an RSI of 28.48. Wall St. Equities' research coverage also includes the downloadable free report on EARS at: http://www.wallstequities.com/registration/?symbol=EARS
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-biotech-equities----viking-therapeutics-rxi-pharma-kitov-pharma-and-auris-medical-300565767.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Sleep paralysis is a condition where one feels unable to move (paralysis) or speak either when ...
Summers days are long, hot and sweaty, and can leave you feeling de-hydrated and tired. Read on to ...
Fosnetupitant and Palonosetron (a fixed antiemetic combination) injection was approved by FDA in ...View All